Is Eli Lilly Stock Heading For A Fall?

Eli Lilly (LLY) is facing threats. Even the biggest names aren’t invincible. Stocks can drop sharply without warning – wiping out months or years of gains in a matter of weeks. History shows that sudden market swings can hit any company, no matter how dominant it seems.

Specifically, we see these risks:

1. Intensifying GLP-1 Price War and Margin Compression
2. Underwhelming Launch of Oral Obesity Drug ‘Foundayo’
3. Escalating Input and Logistics Cost Inflation

Risk 1: Intensifying GLP-1 Price War and Margin Compression

• Details: Erosion of gross margins on flagship Mounjaro and Zepbound products, Valuation de-rating as market shifts from scarcity to high-volume, lower-price model
• Segment Affected: Diabetes and Obesity (GLP-1 Franchise)
• Potential Timeline: Next 2-3 Quarters
• Evidence: Competitor Novo Nordisk projects up to 13% sales decline in 2026 due to ‘unprecedented’ U.S. pricing pressure (Feb 4, 2026), Lilly CFO acknowledges price will be a ‘drag on growth in the low- to mid-teens’ in 2026 (Feb 4, 2026)

Risk 2: Underwhelming Launch of Oral Obesity Drug ‘Foundayo’

• Details: Failure to meet high revenue expectations for oral GLP-1 franchise, Ceding first-mover advantage and market share to Novo Nordisk’s competing pill
• Segment Affected: Obesity (Oral GLP-1)
• Potential Timeline: Next 2 Quarters
• Evidence: Initial sales data shows Foundayo prescribed only 3,707 times in its second week on market (ended Apr 17, 2026), Rival Novo Nordisk’s oral Wegovy pill clocked 18,410 prescriptions in its second week, nearly 5x higher (Apr 24, 2026)

Risk 3: Escalating Input and Logistics Cost Inflation

• Details: Margin pressure from non-pharmaceutical cost inflation, Potential for 2026 guidance to be impacted by costs not fully forecasted in early Q1
• Segment Affected: Corporate / Operations
• Potential Timeline: Next 2-4 Quarters
• Evidence: National average diesel prices surged to $5.61/gallon, up 56% year-over-year (Apr 15, 2026), Construction input prices rose at a 12.6% annualized rate, fueled by energy spikes (Mar 19, 2026)

What Is The Worst That Could Happen?

Looking at LLY, the stock still takes noticeable hits during market turmoil. It fell about 51% in the Global Financial Crisis and around 43% in the Dot-Com bust. Smaller shocks like 2018, Covid, and the Inflation Shock still caused drops around 18-22%. Risk is real despite solid fundamentals.

Is Risk Showing Up In Financials Yet?

• Revenue Growth: 44.7% LTM and 32.1% last 3-year average.
• Cash Generation: Nearly 9.2% free cash flow margin and 45.6% operating margin LTM.
• Valuation: Eli Lilly stock trades at a P/E multiple of 38.4

*LTM: Last Twelve Months

If you want more details, read Buy or Sell LLY Stock.

The Right Way To Invest Is Through Portfolios

Single stocks swing wildly, but staying invested matters. A well-built portfolio helps you stay invested, captures upside, and softens the blows from individual stocks.

The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? HQ Portfolio has posted more than 105% in cumulative return since inception, with less risk versus the benchmark index, as evident in HQ Portfolio performance metrics.

Footnotes

Intensifying GLP-1 Price War and Margin Compression
[1] Eli Lilly’s GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026 – CNBC
Underwhelming Launch of Oral Obesity Drug ‘Foundayo’
[2] Lilly’s obesity pill records modest second week as battle with Novo intensifies – Reuters
Escalating Input and Logistics Cost Inflation
[5] Rising Trucking Costs Signal a Shift to a Supply-Driven Market
[6] Rising raw material costs and geopolitical tensions impact the markets for flexible packaging materials
[7] Construction prices spiked at ‘staggering’ rate to begin 2026